Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC By Ogkologos - July 27, 2026 129 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ELEVATE study Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR Cancer Research UK publishes gender and ethnicity pay gap reports January 20, 2022 Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer June 4, 2020 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Why people and culture matter in research August 10, 2021 Load more HOT NEWS 2020 round-up: Our biggest cancer stories of the year The Cancer Moonshot: A Midpoint Progress Update How cancer hijacks cell death: a new view of metastasis FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller
